Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ezetimibe, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; povidone - adults (greater than or equal to 18 years) primary hypercholesterolaemia: - zient administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia. homozygous familial hypercholesterolaemia (hofh): - zient, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis). homozygous sitosterolaemia (phytosterolaemia): - zient is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.,,prevention of cardiovascular disease zient is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche) heterozygous familial hypercholesterolaemia (hefh): - zient co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:- patients not appropriately controlled with a statin or ezetimibe alone; - patients already treated with a statin and ezetimibe homozygous familial hypercholesterolaemia (hofh): -zient co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis)

Australia - English - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 43168 - non-constrained polyethylene acetabular liner - this acetabular insert is the inner portion of a two-piece acetabulum prosthesis that is sterile and made of x3 polyethylene (highly cross-linked uhwmpe). inserted into an acetabular shell, to articulate with an artificial femoral head as part of a total hip arthroplasty (tha). the insert allows rotational alignment using 12 indexable scallops. four alignment studs on the shell provide rotational and axial alignment. 3mm superior polyethylene lip. a component of a total hip joint prosthesis that is used to replace or repair the acetabulum. indications ? painful, disabling joint disease of the hip resulting from: degenerative arthritis, rheumatoid arthritis, post-traumatic arthritis or late stage avascular necrosis. ? revision of previous unsuccessful femoral head replacement, cup arthroplasty or other procedure. ? clinical management problems where arthrodesis or alternative reconstructive techniques are less likely to achieve satisfactory results. ? where bone stock is of poor quality or is inadequate for other reconstructive techniques as indicated by deficiencies of the acetabulum.

United States - English - NLM (National Library of Medicine)

lannett company, inc. - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 50 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets, usp and other antibacterial drugs, doxycycline tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline tablets, usp are indicated for the treatment of the following infections:     rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae .     respiratory tract infections caused by mycoplasma pneumoniae .     lymphogranuloma venereum caused by chlamydia trachomatis .     psittacosis (ornithosis) caused by chlamydophila psittaci .     trachoma caused by chlamydia trachomatis

United States - English - NLM (National Library of Medicine)

the medicines company - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 100 mg - minocin ® intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox and tick fevers caused by rickettsiae. respiratory tract infections caused by mycoplasma pneumoniae . lymphogranuloma venereum caused by chlamydia trachomatis . psittacosis (ornithosis) due to chlamydophila psittaci . trachoma caused by chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis caused by chlamydia trachomatis . nongonococcal urethritis, endocervical, or rectal infections in adults caused by ureaplasma urealyticum or chlamydia trac

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - travoprost, quantity: 40 microgram/ml; timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: ethoxylated hydrogenated castor oil; sodium hydroxide; propylene glycol; hydrochloric acid; sodium chloride; mannitol; boric acid; purified water; polyquaternium-1 - duotrav is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension for whom single agent therapy provides insufficient intraocular pressure reduction.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - doxycycline hyclate - oral capsule - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - doxycycline hyclate - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - doxycycline hyclate - oral capsule - 100mg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - diflufenican; bromoxynil present as the octanoate - emulsifiable concentrate - diflufenican anilide/aniline-nicotinanilide active 25.0 g/l; bromoxynil present as the octanoate nitrile active 250.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ezetimibe, quantity: 10 mg - tablet - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; lactose monohydrate - adults ( greater than or equal to 18 years) primary hypercholesterolaemia ezetrol administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,homozygous familial hypercholesterolaemia (hofh) ezetrol, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,homozygous sitosterolaemia (phytosterolaemia) ezetrol is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.,prevention of cardiovascular disease ezetrol, is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh) ezetrol co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin or ezetimibe alone - patients already treated with a statin and ezetimibe,homozygous familial hypercholesterolaemia (hofh) ezetrol co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis).